So were still talking about GLP-1 right now
Retatrutide may become an option in the future if: Its approved by the MHRA and recommended by NICE, which is likely several years away You havent responded well to existing GLP-1 medications, and a triple agonist offers a different approach worth trying The Phase 3 safety data on heart rate, irregular heartbeats, and dysesthesia are reassuring once its complete For most people in the UK, the choice now is between Wegovy and Mounjaro, supported by a structured weight management service
Here are the best high-protein picks for GLP-1 users at four popular fast food chains
8.6 How soon can I expect to see results from the Glow + KPV peptide blend
A study found that significant increases in the expression of GPX4 and sensitivity to ferroptosis in ACCs, suggesting that inducing ferroptosis may be a promising approach for the treatment of ACCs
Endocrinology (2016) 157(3):124857